| Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant … TM Beer, ED Kwon, CG Drake, K Fizazi, C Logothetis, G Gravis, V Ganju, ... Journal of Clinical Oncology 35 (1), 40-47, 2017 | 740 | 2017 |
| PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer E Castro, N Romero-Laorden, A Del Pozo, R Lozano, A Medina, J Puente, ... Journal of Clinical Oncology 37 (6), 490-503, 2019 | 339 | 2019 |
| Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables J Sastre, ML Maestro, J Puente, S Veganzones, R Alfonso, S Rafael, ... Annals of Oncology 19 (5), 935-938, 2008 | 297 | 2008 |
| Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre … J Garcia-Donas, E Esteban, LJ Leandro-García, DE Castellano, ... The lancet oncology 12 (12), 1143-1150, 2011 | 287 | 2011 |
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Annals of Oncology 28 (7), 1508-1516, 2017 | 274 | 2017 |
| Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ... The Lancet 398 (10295), 131-142, 2021 | 224 | 2021 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 216 | 2017 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 147 | 2023 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 129 | 2022 |
| Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma C Prior, JL Perez-Gracia, J Garcia-Donas, C Rodriguez-Antona, ... PloS one 9 (1), e86263, 2014 | 103 | 2014 |
| Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial P Vink, I Delgado Mingorance, C Maximiano Alonso, B Rubio‐Viqueira, ... Cancer 125 (8), 1301-1312, 2019 | 100 | 2019 |
| Learning-based scheduling of flexible manufacturing systems using ensemble methods P Priore, B Ponte, J Puente, A Gómez Computers & Industrial Engineering 126, 282-291, 2018 | 94 | 2018 |
| Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer M Martin, A Romero, MCU Cheang, JA López García-Asenjo, ... Breast cancer research and treatment 128, 127-136, 2011 | 93 | 2011 |
| Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma J Garcia-Donas, LJ Leandro-Garcia, AG Del Alba, M Morente, I Alemany, ... Annals of oncology 24 (9), 2409-2414, 2013 | 88 | 2013 |
| Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer V Conteduca, A Jayaram, N Romero-Laorden, D Wetterskog, S Salvi, ... European urology 75 (3), 368-373, 2019 | 81 | 2019 |
| Solving multi-objective rescheduling problems in dynamic permutation flow shop environments with disruptions P Valledor, A Gomez, P Priore, J Puente International Journal of Production Research 56 (19), 6363-6377, 2018 | 64 | 2018 |
| Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting J Puente, E Grande, A Medina, P Maroto, N Lainez, JA Arranz Therapeutic advances in medical oncology 9 (5), 307-318, 2017 | 61 | 2017 |
| DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC … E Grande, F Guerrero, J Puente, I Galante, I Duran, M Dominguez, ... Journal of Clinical Oncology 38 (15_suppl), 5012-5012, 2020 | 58 | 2020 |
| Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer JA García-Sáenz, M Martín, J Puente, S López-Tarruella, A Casado, ... Clinical breast cancer 6 (4), 325-329, 2005 | 57 | 2005 |
| ¿ Qué es el cáncer y cómo se desarrolla J Puente, G de Velasco Sociedad Española de Oncología Médica (SEOM), 2019 | 55 | 2019 |
